LAS VEGAS--(BUSINESS WIRE)--Women with ductal carcinoma in situ (DCIS), an early, non-invasive cancer, who choose surgical removal of both breasts (bilateral mastectomy) to reduce the risk of developing a second cancer in the opposite (contralateral) breast may be over-treated for their disease, suggests new research presented this week at the Annual Meeting of the American Society of Breast Surgeons. A study of 2,750 DCIS patients who underwent breast-conserving lumpectomy surgery found that only 2.8% developed a second contralateral cancer after five years, while only 5.6% did so after 10 years.
Perhaps surprisingly, younger age, positive family breast cancer history, higher nuclear grade disease, clinical presentation and earlier treatment timeframe did not correlate with development of new, contralateral tumors. However, many of these factors were associated with cancer returning in the same (ipsilateral) breast. Overall, an ipsilateral recurrence was more than twice as likely as development of a new cancer in the opposite breast.
“A rapidly growing number of women are choosing double mastectomies for DCIS, perhaps because they misperceive their risk of future cancer. Our research provides important data for treatment decision-making,” explains lead study author Megan Miller, M.D., Breast Surgical Oncology Fellow, Memorial Sloan Kettering Cancer Center. “It suggests patients and their doctors should focus on risk factors and appropriate therapy for the diseased breast, not the opposite breast, and that ipsilateral DCIS should not prompt a bilateral mastectomy.” . . .Cont.
LINK TO FULL PRESS KIT FROM AMERICAN SOCIETY OF BREAST SURGEONS ANNUAL MEETING PRESS CONFERENCE, WITH FULL RELEASE AND ADDITIONAL PRESS RELEASES ON:
- Debunking the Myth of Lymphedema Risk
- Contemporary Inflammatory Breast Cancer Therapy Yields Low Local/Regional Recurrence